Lymphocytes as Biomarkers of Therapeutic Response in Rheumatic Autoimmune Diseases, Is It a Realistic Goal?

about

Personalized medicine in rheumatology: the paradigm of serum autoantibodies.Cutaneous and Mucosal Manifestations of Sjögren's Syndrome.Response to Treatment with TNFα Inhibitors in Rheumatoid Arthritis Is Associated with High Levels of GM-CSF and GM-CSF+ T Lymphocytes.

P2860

Q39432157-36852ECB-09D7-4510-8E85-4B99E03A5893 Q40067064-9FC59455-8DE7-4A2E-A98A-CFEBAE4F5867 Q42113714-542F652A-1756-46FD-B9E2-5B9570F20926

P2860

Lymphocytes as Biomarkers of Therapeutic Response in Rheumatic Autoimmune Diseases, Is It a Realistic Goal?

Item

http://www.wikidata.org/entity/Q38676903

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Lymphocytes as Biomarkers of T ...... eases, Is It a Realistic Goal?

@en

type

Item

label

Lymphocytes as Biomarkers of T ...... eases, Is It a Realistic Goal?

@en

prefLabel

Lymphocytes as Biomarkers of T ...... eases, Is It a Realistic Goal?

@en

P1476

Lymphocytes as Biomarkers of T ...... eases, Is It a Realistic Goal?

@en

P2093

Claire I Daïen

http://www.w3.org/2001/XMLSchema#string

Divi Cornec

http://www.w3.org/2001/XMLSchema#string

Gaetane Nocturne

http://www.w3.org/2001/XMLSchema#string

Kristina Schreiber

http://www.w3.org/2001/XMLSchema#string

P2860

Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine.

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Standardizing Flow Cytometry Immunophenotyping Analysis from the Human ImmunoPhenotyping Consortium

High-Grade Salivary-Gland Involvement, Assessed by Histology or Ultrasonography, Is Associated with a Poor Response to a Single Rituximab Course in Primary Sjögren's Syndrome: Data from the TEARS Randomized Trial.

CD4+,CD28- T cells in rheumatoid arthritis patients combine features of the innate and adaptive immune systems.

NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis.

High levels of memory B cells are associated with response to a first tumor necrosis factor inhibitor in patients with rheumatoid arthritis in a longitudinal prospective study

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab'

Memory B cell subsets and plasmablasts are lower in early than in long-standing rheumatoid arthritis.

Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood.

P2888

s12016-017-8614-7

P31

scholarly article

P356

10.1007/S12016-017-8614-7

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085711808

http://www.w3.org/2001/XMLSchema#string

P698

28560621

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

Lymphocytes as Biomarkers of Therapeutic Response in Rheumatic Autoimmune Diseases, Is It a Realistic Goal?

about

P2860

P2860

Lymphocytes as Biomarkers of Therapeutic Response in Rheumatic Autoimmune Diseases, Is It a Realistic Goal?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P31

P356

P577

P6179

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P31

P356

P577

P6179

P698

P921